These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33546112)

  • 21. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
    Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY.
    Matet A; Daruich A; Zola M; Behar-Cohen F
    Retina; 2018 Jul; 38(7):1403-1414. PubMed ID: 28570485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choroidal thickness in central serous chorioretinopathy.
    Kuroda S; Ikuno Y; Yasuno Y; Nakai K; Usui S; Sawa M; Tsujikawa M; Gomi F; Nishida K
    Retina; 2013 Feb; 33(2):302-8. PubMed ID: 23064424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels.
    Çiloğlu E; Unal F; Dogan NC
    Graefes Arch Clin Exp Ophthalmol; 2018 Jun; 256(6):1111-1116. PubMed ID: 29671064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicentre study of the risk factors associated with recurrence of central serous chorioretinopathy.
    Zhou X; Komuku Y; Araki T; Hozumi K; Terasaki H; Miki A; Kuwayama S; Niki M; Matsubara H; Kinoshita T; Nishi T; Gomi F
    Acta Ophthalmol; 2022 Dec; 100(8):e1729-e1736. PubMed ID: 35633142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Avastin in management of central serous chorioretinopathy.
    Mehany SA; Shawkat AM; Sayed MF; Mourad KM
    Saudi J Ophthalmol; 2010 Jul; 24(3):69-75. PubMed ID: 23960879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy.
    Yavuz S; Balsak S; Karahan M; Dursun B
    J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
    Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.
    Mrejen S; Balaratnasingam C; Kaden TR; Bottini A; Dansingani K; Bhavsar KV; Yannuzzi NA; Patel S; Chen KC; Yu S; Stoffels G; Spaide RF; Freund KB; Yannuzzi LA
    Ophthalmology; 2019 Apr; 126(4):576-588. PubMed ID: 30659849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study.
    Haga F; Maruko R; Sato C; Kataoka K; Ito Y; Terasaki H
    PLoS One; 2017; 12(7):e0181479. PubMed ID: 28742138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
    Demircan A; Yesilkaya C; Alkin Z
    Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy.
    Kwak JH; Hong SW; Ra H; Kim EC; Kang NY; Baek J
    Korean J Ophthalmol; 2019 Dec; 33(6):493-499. PubMed ID: 31833245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transpupillary thermotherapy for atypical central serous chorioretinopathy.
    Kawamura R; Ideta H; Hori H; Yuki K; Uno T; Tanabe T; Tsubota K; Kawasaki T
    Clin Ophthalmol; 2012; 6():175-9. PubMed ID: 22331974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. POLYPOIDAL CHOROIDAL VASCULOPATHY ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY: Pachychoroid Spectrum of Diseases.
    Manayath GJ; Shah VS; Saravanan VR; Narendran V
    Retina; 2018 Jun; 38(6):1195-1204. PubMed ID: 28445211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced Blood Serotonin Levels in Chronic Central Serous Chorioretinopathy.
    Sakai T; Tsuneoka H
    Ophthalmol Retina; 2017; 1(2):145-148. PubMed ID: 31047270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Kumashiro S; Takagi S; Itokawa T; Tajima A; Kobayashi T; Hori Y
    BMC Ophthalmol; 2021 May; 21(1):241. PubMed ID: 34053440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.
    Konstantinidis L; Mantel I; Zografos L; Ambresin A
    Eur J Ophthalmol; 2010; 20(5):955-8. PubMed ID: 20306440
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.